[go: up one dir, main page]

WO2006034451A3 - Bromhydrate de clopidogrel cristallin et procede de preparation correspondant - Google Patents

Bromhydrate de clopidogrel cristallin et procede de preparation correspondant Download PDF

Info

Publication number
WO2006034451A3
WO2006034451A3 PCT/US2005/034149 US2005034149W WO2006034451A3 WO 2006034451 A3 WO2006034451 A3 WO 2006034451A3 US 2005034149 W US2005034149 W US 2005034149W WO 2006034451 A3 WO2006034451 A3 WO 2006034451A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
preparation
clopidogrel hydrobromide
crystalline clopidogrel
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/034149
Other languages
English (en)
Other versions
WO2006034451A2 (fr
Inventor
Nina Finkelstein
Judith Aronhime
Limor Tessler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to JP2006541522A priority Critical patent/JP2007513889A/ja
Priority to EP05798184A priority patent/EP1704152A2/fr
Publication of WO2006034451A2 publication Critical patent/WO2006034451A2/fr
Publication of WO2006034451A3 publication Critical patent/WO2006034451A3/fr
Priority to IL181867A priority patent/IL181867A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des formes cristallines de bromhydrate de clopidogrel, ainsi que des procédés permettant de les préparer.
PCT/US2005/034149 2004-09-21 2005-09-21 Bromhydrate de clopidogrel cristallin et procede de preparation correspondant Ceased WO2006034451A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006541522A JP2007513889A (ja) 2004-09-21 2005-09-21 結晶性クロピドグレル臭酸塩及びその調製方法
EP05798184A EP1704152A2 (fr) 2004-09-21 2005-09-21 Hydrobromure cristallin de clopidogrel et ses procedes de preparation
IL181867A IL181867A0 (en) 2004-09-21 2007-03-12 Crystalline clopidogrel hydrobromide and processes for preparation thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61199504P 2004-09-21 2004-09-21
US60/611,995 2004-09-21
US61577104P 2004-10-04 2004-10-04
US60/615,771 2004-10-04

Publications (2)

Publication Number Publication Date
WO2006034451A2 WO2006034451A2 (fr) 2006-03-30
WO2006034451A3 true WO2006034451A3 (fr) 2006-08-10

Family

ID=35500763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034149 Ceased WO2006034451A2 (fr) 2004-09-21 2005-09-21 Bromhydrate de clopidogrel cristallin et procede de preparation correspondant

Country Status (6)

Country Link
US (4) US20060154957A1 (fr)
EP (1) EP1704152A2 (fr)
JP (1) JP2007513889A (fr)
KR (1) KR20070052780A (fr)
IL (1) IL181867A0 (fr)
WO (1) WO2006034451A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297570B6 (cs) * 2000-12-25 2007-02-07 Sankyo Company, Limited Farmaceutický prípravek obsahující 2-acetoxypyridinový derivát a aspirin, které spolu pusobí v synergickém úcinku, kit jej obsahující a pouzití
EP2103617A1 (fr) * 2003-11-03 2009-09-23 Cadila Healthcare Limited Processus de préparation de différentes formes de bisulfate de clopidogrel (S)-(+)
WO2006034451A2 (fr) * 2004-09-21 2006-03-30 Teva Pharmaceutical Industries Ltd. Bromhydrate de clopidogrel cristallin et procede de preparation correspondant
CA2594763A1 (fr) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Clopidogrel base convenant a une formulation pharmaceutique et preparation de ce clopidogrel base
US20090247569A1 (en) * 2006-08-03 2009-10-01 Claude Singer Process for Preparing Clopidogrel Bisulphate
EP1970054A3 (fr) 2007-03-14 2009-06-03 Ranbaxy Laboratories Limited Comprimés de clopidogrel
EP3766493B1 (fr) 2007-04-27 2023-08-23 CyDex Pharmaceuticals, Inc. Méthode de stabilisation du clopidogrel en utilisant de la sulfoalkyl-éther cyclodextrine
CN101427992B (zh) * 2007-11-07 2011-02-09 浙江华海药业股份有限公司 氯吡格雷氢溴酸盐制剂及其制备方法
EP2107061A1 (fr) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de clopidogrel enrichi optiquement
KR101743591B1 (ko) 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
CN101766573B (zh) 2010-02-05 2013-02-13 上海安必生制药技术有限公司 硫酸氢氯吡格雷固体制剂的制备工艺
EP2595971A1 (fr) 2010-07-23 2013-05-29 Grünenthal GmbH Sels ou co-cristaux de 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)- phénol
WO2012123958A1 (fr) 2011-02-14 2012-09-20 Cadila Healthcare Limited Sels très purs de clopidogrel exempts d'impuretés génotoxiques
CR20160222U (es) 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847265A (en) * 1987-02-17 1989-07-11 Sanofi Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it
WO2005026174A1 (fr) * 2003-09-11 2005-03-24 Generics [Uk] Limited Polymorphes cristallins du clopidogrel
WO2005103058A1 (fr) * 2004-04-20 2005-11-03 Sanofi-Aventis Formes polymorphes d'hydrobromure d'acetate de methyl(+)-(s)-$g(a)-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h), hydrobromure de clopidrogel

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US600875A (en) * 1898-03-22 Earth-auger
US4132435A (en) * 1977-06-30 1979-01-02 Ken Wilson Departures, Inc. Steerable wheeled vehicle
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2652575B1 (fr) * 1989-09-29 1992-01-24 Sanofi Sa Procede de preparation d'acides alpha-bromo phenylacetiques.
FR2664276B1 (fr) * 1990-07-04 1992-10-23 Sanofi Sa Derive thienyl-2 glycidique, son procede de preparation et son utilisation comme intermediaire de synthese.
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
FR2760456B1 (fr) * 1997-03-05 2000-05-12 Sanofi Sa Procede de preparation de derives de 2-thienyl-ethylamine
HU222283B1 (hu) * 1997-05-13 2003-05-28 Sanofi-Synthelabo Eljárás tieno[3,2-c]piridin-származékok előállítására
HU225503B1 (en) * 1997-05-13 2007-01-29 Sanofi Aventis Novel 2-(2-halophenyl)-2-(2-(2-thienyl)-ethylamino)-acetamides and process for producing them
HU225504B1 (en) * 1997-05-13 2007-01-29 Sanofi Aventis Novel halophenyl-(2-(2-thienyl)-ethylamino)-acetonitriles and process for producing them
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US6767913B2 (en) * 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) * 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
IL166593A0 (en) * 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
US20060258677A1 (en) * 2003-02-15 2006-11-16 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin and processes for preparation
WO2006034451A2 (fr) * 2004-09-21 2006-03-30 Teva Pharmaceutical Industries Ltd. Bromhydrate de clopidogrel cristallin et procede de preparation correspondant
CA2594763A1 (fr) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Clopidogrel base convenant a une formulation pharmaceutique et preparation de ce clopidogrel base

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847265A (en) * 1987-02-17 1989-07-11 Sanofi Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it
WO2005026174A1 (fr) * 2003-09-11 2005-03-24 Generics [Uk] Limited Polymorphes cristallins du clopidogrel
WO2005103058A1 (fr) * 2004-04-20 2005-11-03 Sanofi-Aventis Formes polymorphes d'hydrobromure d'acetate de methyl(+)-(s)-$g(a)-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h), hydrobromure de clopidrogel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Synthesis of the stable polymorph I of Clopidogrel hydrobromide", RESEARCH DISCLOSURE, MASON PUBLICATIONS, HAMPSHIRE, GB, vol. 490, no. 4, 19 January 2005 (2005-01-19), XP007134723, ISSN: 0374-4353 *

Also Published As

Publication number Publication date
IL181867A0 (en) 2007-07-04
US20080300409A1 (en) 2008-12-04
US20080306268A1 (en) 2008-12-11
KR20070052780A (ko) 2007-05-22
JP2007513889A (ja) 2007-05-31
EP1704152A2 (fr) 2006-09-27
US20090187022A1 (en) 2009-07-23
WO2006034451A2 (fr) 2006-03-30
US20060154957A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
IL181867A0 (en) Crystalline clopidogrel hydrobromide and processes for preparation thereof
WO2006023627A8 (fr) Polymorphes de rapamycine et leurs utilisations
WO2008021342A3 (fr) Formes cristallines de la 9-hydroxy-rispéridone (palipéridone)
WO2008027600A3 (fr) Compositions d'imatinib
WO2010056656A3 (fr) Synthèse de chlorhydrate de palonosétron cristallin
WO2006012379A3 (fr) Procedes de preparation de mycophenolate sodique cristallin
WO2007010555A3 (fr) Nouvelles formes cristallines d'hydrochlorure de moxifloxacine et procede de preparation associe
WO2008019103A3 (fr) Formes de solifénacine base et leur préparation
WO2005102999A3 (fr) Formes cristallines d'hydrochlorure de fexofenadine, et procedes pour les preparer
WO2008157563A3 (fr) Clopidogrel enrichi en deutérium
EP2249287B8 (fr) Procédé d'enregistrement
WO2007081907A3 (fr) Formes cristallines de la base dolasetron et leurs procédés de préparation
ZA200703495B (en) Process for the preparation of irbesartan hydrochloride
WO2006091847A3 (fr) Clopidogrel base convenant a une formulation pharmaceutique et preparation de ce clopidogrel base
WO2006074230A3 (fr) Procede de fabrication d'hydrochlorure de dorzolamide
WO2007002314A3 (fr) Formes polymorphes de maleate de tegaserod
WO2007038676A3 (fr) Formes polymorphiques de ladostigil tartrate
WO2006098834A3 (fr) Formes cristallines de mesylate de ziprasidone
WO2008021518A3 (fr) Formes cristallines d'hydrochlorure de tiagabine
WO2007146341A3 (fr) Formes amorphes et cristallines de pantoprazole sel de magnésium
WO2008039492A3 (fr) Formes cristallines de valrubicine et procédés de préparation
WO2006048665A3 (fr) Composes chimiques
WO2006077584A3 (fr) Nouvelles formes cristallines d'aripiprazole
WO2009087667A3 (fr) Nouveau procédé de préparation de zopiclone et de ses polymorphes
WO2006078731A3 (fr) Formes amorphes et cristallines de d'hydrochlorure de dorzolamide et leurs procedes de fabrication

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005798184

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006541522

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2005798184

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1128/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020077005407

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 181867

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE